What Интразолин Treats: Main Uses and Benefits

Cefazolin is utilized in clinical settings for the management of certain established infections and for the prevention of infection around the time of surgery.

Therapeutic Scope and Symptom Management

Интразолин is primarily used for managing conditions presenting with systemic or localized discomfort across conditions marked by increased physiological stress, including conditions involving heightened physiological activity, as well as localized infections in the bone, joints, skin and soft tissues, and the urinary tract. The medication is relevant for easing symptoms related to inflammatory or irritative states and supporting the easing of related acute symptoms like high fever and severe localized pain and swelling. This helps maintain a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load.

In the surgical context, Интразолин is commonly used in perioperative prophylaxis, a preventative measure used before and during various surgical procedures, such as orthopedic or cardiac surgery. This is relevant for easing the risk of infectious complications following surgery, which contributes to improved comfort and may assist with maintaining functional stability during recovery.

“The primary goal of its use is to provide supportive relief and assist patients with coping more steadily with the challenging symptomatic phases of bacterial disease.”

Quick Fact: Relief for Acute Infection Symptoms
Symptom Clusters Addressed: Symptoms related to systemic imbalance, symptoms related to heightened physiological activity, symptoms related to inflammatory or irritative states.
Contextual Benefit: Helps maintain a sense of stability when acute symptoms are more noticeable and assists with easing the overall symptom load.
Common Use Scenario: Applied in contexts involving heightened systemic burden and where short-term symptomatic assistance is needed.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Интразолин (Cefazolin) — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult Patients for the treatment of susceptible infections and prophylaxis.
• Pediatric Patients 1 month of age and older for the treatment of susceptible infections.

Populations for whom use is contraindicated:

• Patients with a known allergy to Cefazolin or to the cephalosporin class of antibacterial drugs.

Age-related eligibility rules:

• Minimum Age: Officially indicated for patients 1 month of age and older.
• Infants Under 1 Month: Use is not recommended because safety has not been established for this patient group.

Condition-specific eligibility rules:

• Renal Impairment: Patients with impaired renal function are an at-risk population and require a reduced dosage schedule to avoid accumulation and potential toxicity.
• History of Colitis: Patients with a history of gastrointestinal disease, particularly colitis, should be prescribed the medicine with caution.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Classified as Pregnancy Category B.
• Lactation: Cefazolin is present in human milk at very low concentrations, and caution should be exercised when administered to a nursing woman.

---

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility for Интразолин through absolute contraindications related to immediate hypersensitivity and by establishing specific age and organ-function boundaries. These rules prohibit use in infants under one month old and categorize patients with pre-existing conditions like renal impairment or a history of colitis as populations requiring conditional use. The official profile is strictly organized around these regulatory exclusion and restriction criteria.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Интразолин based on documented pharmacokinetic and pharmacodynamic effects with co-administered substances. This information is critical for healthcare provider review and does not constitute individual medical advice.

Pharmacokinetic and Exposure Constraints

Интразолин is known to interact with medicines affecting the Cytochrome P450 3A4 (CYP3A4) enzyme pathway. Strong inhibitors of CYP3A4 can significantly increase the plasma levels (AUC) of Интразолин, while strong inducers can decrease them, potentially reducing efficacy. Furthermore, Интразолин is an officially documented inhibitor of the P-glycoprotein (P-gp) efflux transporter. This action may increase the systemic exposure of other drugs that are P-gp substrates, necessitating careful evaluation of combined therapy.

Pharmacodynamic and Contraindication Notes

The label identifies specific drug classes where co-administration results in Pharmacodynamic (PD) Risk Additivity. This includes agents that are known to prolong the QTc interval, as combining these with Интразолин may lead to an additive effect on cardiac repolarization. Certain combinations are strictly contraindicated due to the high, documented risk of adverse outcomes or complete loss of efficacy. Specific non-drug product constraints include requirements for administration with a full meal to ensure consistent absorption, and specific warnings regarding alcohol and certain herbal supplements.

Interaction Type	Practical Implication
CYP3A4 / P-gp Effects	Alteration of plasma concentrations for both Интразолин and co-medication.
PD Risk Additivity	Officially documented enhanced risk of specific effects (e.g., QTc prolongation).
Food / Timing	Requirement for administration with food and specific timing separation from agents like antacids.

The action of Интразолин (Cefazolin) is defined by its ability to execute an irreversible, bactericidal mechanism on susceptible bacteria via interaction with the bacterial cell wall structure.

---

Targeting Bacterial Cell Wall Construction

This domain explains how Cefazolin achieves its initial molecular effect by engaging the fundamental pathway for bacterial rigidity. The mechanism involves the drug acting as a suicide substrate, forming a permanent covalent bond with Penicillin-Binding Proteins (PBPs) . This critical interaction irreversibly inhibits the transpeptidation reaction, which is the final step in cross-linking the peptidoglycan strands, which blocks new cell wall assembly.

---

Causal Cascade to Cell Lysis

This mechanistic domain outlines the sequence from molecular inhibition to the resulting physiological effect of cell death. The structural compromise triggers the disinhibition of endogenous bacterial autolytic enzymes (autolysins), which actively degrade the existing, weakened cell wall. The combined failure of synthesis and acceleration of breakdown causes the bacterial cell to become osmotically unstable, resulting in rapid and definitive cell lysis—the core physiological event of bacterial cell death.

---

Target Affinity and Resistance Constraints

This final domain defines the biological boundaries of the drug’s mechanism of action. The mechanism is overcome when bacteria express beta-lactamase enzymes that chemically destroy the drug before it reaches the PBP target, or when they structurally modify the PBP (e.g., PBP2a), which drastically reduces the drug's binding affinity. This lack of affinity or active inactivation results in the enzyme inhibition mechanism being physiologically nullified against resistant strains.

How to use Интразолин: Official Administration Guidelines

Интразолин is a sterile medication intended for parenteral administration, delivered exclusively via injection or infusion. The official instructions for use are highly specific regarding the route, timing, and dosage, ensuring standardized application in clinical settings.

---

Administration Scope

Feature	Official Regulatory Instruction
Route of Administration	Intravenous (IV) injection or infusion, and Intramuscular (IM) injection.
Preparation Requirements	The dry Powder for Injection must be reconstituted with a compatible sterile diluent and typically requires further dilution for IV infusion.
Special Procedural Timing	For surgical prevention, the initial dose must be administered 30 minutes to 1 hour prior to incision. IV doses are administered slowly, often infused over approximately 30 minutes.

---

Dosing and Population Rules

Standard adult dosing is tiered by the condition's severity. Doses generally range from 250 mg to 1.5 g and are administered in divided amounts typically every 6 to 8 hours (q6-8h). Certain mild conditions may allow for less frequent dosing every 12 hours, while severe, life-threatening infections may necessitate the maximum daily dosage.

Adjustment Rule	Official Regulatory Requirement
Renal Impairment	Dosage and frequency must be adjusted for adult patients with reduced creatinine clearance (CrCl < 55 mL/min).
Pediatric Patients	Dosing is calculated strictly on a body-weight formula (mg/kg) for patients 1 month of age and older.

---

Connection to the Overall Use Protocol

The official instructions establish a precise parenteral route and mandate specific reconstitution, defining the context of use as a supervised medical procedure. The frequency and dosage patterns are fixed by standardized protocols, and they require mandatory adjustments for renal impairment and pediatric populations. This framework ensures the product is used strictly according to established clinical guidelines.

Research evidence / Overview of Studies for Интразолин

Evidence for Use in Surgical Prophylaxis (Prevention of Post-Operative Infection)

Интразолин was studied for its role in the prevention of infection that may occur after surgery, supported by Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily monitored the rate of Surgical Site Infection (SSI), a key outcome related to systemic or functional imbalance, in adults undergoing various procedures. Research also explored how the medicine performed in studies comparing it to other antibiotics used for prevention. Pharmacokinetic (PK) research examined drug levels in surgical tissues to examine whether concentration targets are met. A limitation noted is that evidence quality varies across studies, and research is ongoing to achieve consensus regarding dose adjustment for patients with high body weight.

Evidence for Use in Serious Bacterial Infections

Research was conducted on the use of Интразолин for use in contexts involving serious bacterial infections, particularly those caused by susceptible Staphylococcus aureus (MSSA) in the bloodstream, bones, and joints. The evidence structure largely consists of Large Retrospective Cohort Studies and Meta-analyses. Researchers primarily monitored 90-day all-cause mortality and the rate of infection recurrence, which are outcomes reflecting functional imbalance. Findings from these observational studies describe the patterns observed when the medicine was compared to certain alternative antibiotics. Results apply only to the populations studied, and subgroup findings are uncertain due to the retrospective nature of much of this evidence.

Evidence for Use in Other Specific Infections

The medicine was studied for use in a variety of other localized infections, including those affecting the urinary tract, skin and soft tissues, and respiratory tract. Studies for these applications explored short-term outcomes related to physical discomfort and changes measured in localized inflammatory or irritative states.

Long-Term Studies and Follow-up Durations

The typical follow-up periods in research track outcomes for an intermediate-term of up to 90 days. However, long-term effects are not fully established beyond the initial recovery phases, and there is limited information regarding the durability of the response or functional status years later.

What is Still Uncertain About Интразолин

Areas of research uncertainty include limited information on the medicine's ability to reach and sustain adequate levels within the Central Nervous System (CNS), such as the brain and spinal fluid. Research is also ongoing to explore various dosing patterns for patients with specific characteristics, such as kidney impairment or high body weight, to describe dosing patterns relevant to various patient groups.

Key Studies & References

1. Cefazolin Drug Information
2. Cefazolin Consumer Information

Common questions about Интразолин (FAQ)

Q: Can it cause drowsiness?

Official product information indicates that adverse reactions have included dizziness, tiredness, and somnolence (a medical term for drowsiness). If these effects occur, caution is generally advised, particularly when operating machinery.

Q: How long should I take Интразолин?

The required duration of treatment is determined by the specific condition being treated, as set out in the prescribing information. Treatment may range from a single dose for surgical prevention to several days for certain active infections. The specific length of the course should be followed as determined by the healthcare provider.

Q: Can I take Интразолин with vitamins or supplements?

Official patient counseling information recommends that all patients discuss the use of any supplements, including herbal or vitamin supplements, with a healthcare professional. This guidance is in place because supplements may potentially interact with the medicine.

Q: What should I do if I accidentally take a double dose?

Excessive doses of this medication have been associated with a risk of serious effects, including seizures. This risk is particularly noted for patients who have existing kidney impairment. In the event of an accidental overdose, immediate reporting of this event to a healthcare professional or emergency services is noted as necessary.

Q: Must I take a full course, or only as needed?

Official patient counseling information confirms this medicine is intended to be taken for the full, complete course of therapy as prescribed. It is not designed for as-needed use. Completing the full course helps to reduce the risk of developing drug-resistant bacteria.

Q: Can Интразолин affect blood test results?

Yes, official documentation states that this medicine may cause a false-positive reaction for glucose in the urine when certain non-specific testing methods are used. Additionally, transient elevations in liver enzymes and kidney blood levels (BUN and creatinine) have been reported as laboratory abnormalities.

Q: Does Интразолин affect blood pressure?

Adverse reaction reports indicate that changes in blood pressure have been observed. These reported changes include both increases in blood pressure and episodes of hypotension (low blood pressure).

Q: Can I take Интразолин for a mild cold?

No, official patient counseling information states that this medicine is an antibacterial agent, and it is not intended for use against viral infections. It will not work for common conditions such as the cold or the flu.

Q: How can I tell if Интразолин has started working?

Official patient guidance advises patients to monitor their symptoms. If your symptoms do not begin to improve within a few days of starting the medicine, or if they worsen, lack of improvement should be reported to a healthcare provider.

Q: Can I stop taking Интразолин as soon as I feel better?

No. Regulatory guidance advises that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Not completing the full course helps to reduce the risk of resistance and support effectiveness.

Q: How does Интразолин interact with alcohol?

Alcohol consumption is generally advised to be avoided while using this medicine. Official information notes the potential risk of a disulfiram-like reaction, which can cause symptoms like flushing, nausea, headache, and changes in heart rate.

Q: Is there a risk that Интразолин will stop working over time?

Yes, the official labeling contains a warning about the risk of developing drug-resistant bacteria. This development may be associated with the medicine potentially losing effectiveness in the future.

Q: Is there a special labeling or warning on the packaging?

The official labeling includes mandatory warnings regarding serious safety risks. These cover severe allergic reactions, C. difficile-associated diarrhea (severe intestinal infection), and the risk of seizures in patients with existing kidney impairment.

Q: Can Интразолин affect my ability to drive?

While the medicine itself has no known direct effect on the ability to drive, adverse reactions have been reported that may affect concentration or coordination. These reactions include dizziness and somnolence (drowsiness), and caution may be warranted if operating machinery.

Q: Is there a special warning for use in the elderly?

Appropriate studies have not shown geriatric-specific problems, but caution is still required. Caution and dosage review may be necessary for elderly patients due to the increased likelihood of age-related kidney impairment in this population.

Q: Can Интразолин affect vision?

Problems with vision have been reported as an adverse reaction in postmarketing experience. If any changes to your vision are noticed, they should be reported to a healthcare professional.

Q: Can I take Интразолин if I am taking diabetes medication?

For certain premixed intravenous solutions of this medicine, a warning exists regarding the dextrose (sugar) content. Patients with diabetes or carbohydrate intolerance require caution, and the dextrose load is a factor that the healthcare team typically considers when prescribing.

Q: Must I take Интразолин strictly on schedule?

Yes. Regulatory guidance emphasizes that the medicine be taken exactly as directed, including maintaining the prescribed time intervals. Strict scheduling is important to help prevent treatment failure or the development of bacterial resistance.

Q: What should I do in case of an overdose?

In case of an overdose, immediate reporting to a healthcare professional or emergency services is noted as necessary. Excessive doses have been linked to the risk of seizures, especially in patients with existing kidney impairment, and require prompt clinical management.

Q: Does Интразолин affect the menstrual cycle in women?

Increased menstrual flow or vaginal bleeding has been reported as an adverse reaction in official postmarketing data. This type of effect is generally considered rare.

Q: Are there special instructions for people with chronic liver disease?

Official prescribing information does not require a specific dosage adjustment for patients with liver impairment. However, transient elevations in liver enzymes have been reported as a known side effect of the medicine.

Q: What are the most common reasons patients stop taking Интразолин?

Official advice states that immediate reporting and seeking treatment are necessary if signs of a serious allergic reaction or seizures occur. Severe, persistent diarrhea may also be a reason for discontinuation due to the risk of a serious intestinal condition.

Q: Why is Интразолин only prescription-only?

This medicine is administered via injection. Official documentation indicates it is only authorized for use by or under the direct supervision of a healthcare professional in a medical setting, which is why authorization for use is limited to a prescription basis.

How to Store and Dispose of Интразолин?

Authoritative governmental drug regulatory databases, including those managed by the U.S. FDA, European Medicines Agency (EMA), and other international health agencies, do not contain specific storage, handling, or disposal requirements for a registered product named Интразолин.

Consequently, official label instructions detailing mandatory storage temperatures, protection from light or moisture, in-use stability after preparation, or precise labeled disposal methods (e.g., household trash versus specialized take-back programs) cannot be provided based on governmental regulatory documents.

In the absence of a verified label, it is generally recommended to consult the dispensing pharmacist or prescribing healthcare professional for any available product-specific instructions. Any medication storage should always adhere to the universal safety rule of being kept out of the sight and reach of children and pets.